Clinuvel Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Clinuvel Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Clinuvel Pharmaceuticals Ltd Strategy Report
- Understand Clinuvel Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) is a biopharmaceutical company that focuses on the development of drugs for the treatment of light-related severe skin disorders. The company’s lead product candidate, Scenesse (afamelanotide) is a first-in-class drug targeting erythropoietic protoporphyria (EPP) and is approved in Europe, Australia and the US for treating adult EPP patients. Its other pipeline products include CUV9900 and VLRX001 among others. Clinuvel Pharmaceuticals also focused on developing a pediatric formulation of Scenesse for EPP and OTC products for general photoprotective application. The company through its subsidiaries has operations in Australia, Switzerland, Ireland, the UK, the US, and Singapore. Clinuvel Pharmaceuticals is headquartered in Melbourne, Victoria, Australia.
Headquarters
Australia
Address
Level 22, 535 Bourke Street, Melbourne, Victoria, 3000
Website
www.clinuvel.com
Telephone
61 3 96604900
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CUV (ASX)
Revenue (2022)
$57.0M
24.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
46.6%
(2022 vs 2021)
Market Cap*
$492.1M
Net Profit Margin (2022)
XYZ
18.0%
(2022 vs 2021)
* As of and is in US$
Clinuvel Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Commercial: | - |
| Scenesse (Afamelanotide) | Prenumbra |
| Pipeline products: | Scenesse |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In March, CLINUVEL launched CYACELLE, a next generation of polychromatic solar care. |
| 2022 | Others | In February, the company announced the first disease-free subjects have received afamelanotide as part of the CUV151 mechanistic study to evaluate the impact of the drug on DNA damaged skin. |
| 2022 | Contracts/Agreements | In January, the company entered into a second agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the ongoing treatment and reimbursement of SCENESSE (afamelanotide 16mg). |
Competitor Comparison
| Key Parameters | Clinuvel Pharmaceuticals Ltd | MEI Pharma Inc | Rhinomed Ltd | Opthea Ltd | Biosensis Pty Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Australia | Australia | Australia |
| City | Melbourne | San Diego | Richmond | Melbourne | Thebarton |
| State/Province | Victoria | California | Victoria | Victoria | South Australia |
| No. of Employees | 16 | 46 | - | 5 | - |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Philipe J. Wolgen, Ph.D. | Chief Executive Officer; Director; Managing Director | Executive Board | 2005 | - |
| Darren M. Keamy | Chief Financial Officer; Secretary | Senior Management | 2006 | - |
| Dennis Wright, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Jeffrey Rosenfeld | Chairman | Non Executive Board | 2024 | - |
| Lachlan Hay | Director - Global Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward